Synecta™ T1 - 1 mL

Synecta™ T1 is the next-generation T-cell activation technology developed to optimize ex vivo cell therapy manufacturing. Unlike conventional CD3/CD28 activation beads, Synecta uses biodegradable cell-derived nanoparticles (CDNPs) engineered to present membrane-bound activation, co-stimulatory and cytokine signals that recreate key features of the natural immune synapse for more physiological T-cell activation.

This approach promotes robust T-cell activation and expansion while maintaining a high proportion of stem cell-like and central memory T cells associated with improved persistence and therapeutic performance. Synecta also supports both viral and non-viral gene engineering workflows, enabling efficient Day 0 transduction or genome editing without the need for exogenous cytokines during activation.

Designed to simplify manufacturing, Synecta eliminates bead removal, reducing process complexity, hands-on time and cell loss while supporting closed, scalable and automated production workflows. This drives reduced costs, making therapies more accessible for patients.

Synecta T1 is suitable for a wide range of applications, including CAR-T, TCR-T, iNKT cell and viral and non-viral immune cell manufacturing, supporting researchers from preclinical research through clinical translation.

Product Specifications:

· Recommended starting dose: 30 μL Synecta™ T1 per 1 × 10⁶ T cells

· Compatible with serum-free and serum-containing media

· Recommended for Day 0 lentiviral transduction

· No bead removal required

· Adaptable to cell isolation methods, culture media and bioreactor platforms

· Easy-to-use workflow with robust, dose-dependent T-cell expansion